
Opinion|Videos|January 15, 2025
Additional Safety Considerations With PBC Treatments
Panelists discuss how managing primary biliary cholangitis (PBC) in women of childbearing age requires careful consideration of pregnancy risk categories for different medications, with UDCA being the safest option during pregnancy, while second-line therapies require strict contraception and careful monitoring of hormone interactions to ensure optimal safety and efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How should clinicians approach fetal toxicity risks with PBC treatments, especially when managing women of childbearing age, and what precautions are recommended?
- Explain the relevance of the interaction between PBC therapies and hormone replacement therapy. How should these interactions be managed to ensure patient safety?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
2
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
3
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
4
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
5










































































































































































































